Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18751704 | 1.00 | MGLL (0.33) | MGLL | |
| SCHEMBL19658322 | 1.00 | MGLL (0.33) | MGLL | |
| SCHEMBL17776326 | 0.93 | MGLL (0.33) | MGLL | |
| SCHEMBL21100434 | 0.93 | MGLL (0.33) | MGLL | |
| SCHEMBL18751699 | 0.92 | TP53 (0.35) | MGLL | |
| SCHEMBL20848195 | 0.92 | MGLL (0.33) | MGLL | |
| SCHEMBL18751705 | 0.92 | MGLL (0.33) | MGLL | |
| SCHEMBL19658176 | 0.92 | TP53 (0.35) | MGLL | |
| SCHEMBL26382053 | 0.88 | MGLL (0.30) | MGLL | |
| SCHEMBL15326761 | 0.86 | ALDH1A1 (0.35) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689430-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
| WO-2017205309-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | MGLL 2105/4885 |
| US-10689430-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | MGLL 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.